Q2 EPS Estimates for Verona Pharma Decreased by Analyst

Verona Pharma plc (NASDAQ:VRNA - Free Report) - Equities research analysts at Roth Capital lowered their Q2 2025 earnings per share estimates for Verona Pharma in a report released on Tuesday, April 29th. Roth Capital analyst B. Pachaiyappan now anticipates that the company will post earnings per share of ($0.16) for the quarter, down from their prior estimate of $0.13. The consensus estimate for Verona Pharma's current full-year earnings is ($1.95) per share. Roth Capital also issued estimates for Verona Pharma's Q3 2025 earnings at $0.13 EPS, Q4 2025 earnings at $0.36 EPS, FY2025 earnings at $0.14 EPS and FY2026 earnings at $3.79 EPS.

Verona Pharma (NASDAQ:VRNA - Get Free Report) last posted its quarterly earnings results on Tuesday, April 29th. The company reported $0.27 earnings per share for the quarter, beating analysts' consensus estimates of ($0.22) by $0.49. The company had revenue of $98.65 million during the quarter, compared to analyst estimates of $41.47 million.

A number of other equities analysts have also commented on VRNA. Canaccord Genuity Group lifted their price target on shares of Verona Pharma from $44.00 to $72.00 and gave the stock a "buy" rating in a report on Wednesday, February 12th. Cowen initiated coverage on Verona Pharma in a research report on Monday, April 28th. They set a "buy" rating for the company. Wells Fargo & Company upped their target price on Verona Pharma from $93.00 to $107.00 and gave the company an "overweight" rating in a report on Wednesday, April 30th. Cantor Fitzgerald assumed coverage on shares of Verona Pharma in a report on Monday, April 21st. They set an "overweight" rating and a $80.00 price target for the company. Finally, HC Wainwright boosted their price target on shares of Verona Pharma from $75.00 to $85.00 and gave the stock a "buy" rating in a research report on Wednesday, April 30th. Eight investment analysts have rated the stock with a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat.com, the stock presently has an average rating of "Buy" and an average price target of $81.50.

Verona Pharma Trading Down 3.0 %

NASDAQ VRNA traded down $2.18 during trading hours on Friday, reaching $70.07. The company's stock had a trading volume of 1,101,543 shares, compared to its average volume of 1,267,991. The firm has a fifty day simple moving average of $63.28 and a 200-day simple moving average of $52.41. The company has a debt-to-equity ratio of 0.93, a current ratio of 13.03 and a quick ratio of 12.88. Verona Pharma has a 52 week low of $11.39 and a 52 week high of $74.18. The stock has a market cap of $5.66 billion, a P/E ratio of -36.49 and a beta of 0.20.

Insider Buying and Selling

In other news, insider Kathleen A. Rickard sold 79,264 shares of the company's stock in a transaction that occurred on Wednesday, March 12th. The stock was sold at an average price of $8.35, for a total transaction of $661,854.40. Following the transaction, the insider now directly owns 2,608,976 shares of the company's stock, valued at $21,784,949.60. This represents a 2.95 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, CEO David Zaccardelli sold 90,360 shares of the stock in a transaction on Tuesday, April 29th. The stock was sold at an average price of $8.98, for a total value of $811,432.80. Following the completion of the transaction, the chief executive officer now owns 14,377,176 shares in the company, valued at approximately $129,107,040.48. This represents a 0.62 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 250,080 shares of company stock valued at $2,194,582 over the last ninety days. 4.80% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On Verona Pharma

Several hedge funds have recently modified their holdings of the company. Wellington Management Group LLP lifted its stake in Verona Pharma by 61.0% in the 4th quarter. Wellington Management Group LLP now owns 3,025,241 shares of the company's stock worth $140,492,000 after purchasing an additional 1,146,609 shares in the last quarter. Jennison Associates LLC boosted its stake in shares of Verona Pharma by 8.5% during the fourth quarter. Jennison Associates LLC now owns 1,889,542 shares of the company's stock valued at $87,750,000 after purchasing an additional 148,656 shares during the period. Price T Rowe Associates Inc. MD grew its holdings in Verona Pharma by 37.3% in the 4th quarter. Price T Rowe Associates Inc. MD now owns 1,833,532 shares of the company's stock worth $85,150,000 after acquiring an additional 498,338 shares during the last quarter. RTW Investments LP purchased a new position in Verona Pharma during the 4th quarter valued at about $84,568,000. Finally, Janus Henderson Group PLC increased its stake in shares of Verona Pharma by 59.9% during the fourth quarter. Janus Henderson Group PLC now owns 1,667,165 shares of the company's stock valued at $77,466,000 after buying an additional 624,370 shares during the period. Institutional investors own 85.88% of the company's stock.

About Verona Pharma

Verona Pharma plc, a clinical stage biopharmaceutical company, focuses on development and commercialization of therapies for the treatment of respiratory diseases with unmet medical needs. The company's product candidate is ensifentrine, an inhaled and dual inhibitor of the phosphodiesterase (PDE) 3 and PDE4 enzymes that acts as both a bronchodilator and an anti-inflammatory agent in a single compound, which is in Phase 3 clinical trials for the treatment of chronic obstructive pulmonary disease, asthma, and cystic fibrosis.